A phase II clinical trial investigates tazemetostat, a EZH2 inhibitor, in combination with a fixed dose of pembrolizumab in patients with R/M HNSCC (NCT04624113). This evidence concerns the gene EZH2 and head and neck squamous cell carcinoma.